Founded by Jessica Hanley and David Lisowski, the new independent firm focuses on corporate interiors and complex ...
3d
Budget of €2.2m for cancelled student grant IT project not ‘in any way’ realistic, department says
An initial budget of €2.2 million for a now terminated IT system for processing student grants “did not represent in any way a full or realistic estimate of costs”, the Department of Further and ...
HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -- 48-week trial will enroll approximately 150 ...
FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIASARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a ...
Facility commissioning and qualification (C&Q) success begins with project setup meetings that align stakeholders, project metrics, and mitigate risks.
Irrigation Minister N Uttam Kumar Reddy has called for immediate Phase II desiltation of major irrigation projects to restore storage capacity. He said proposals would be placed before the State Cabin ...
FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-tar ...
VANCOUVER, BC / ACCESS Newswire / March 12, 2026 / Faraday Copper Corp. ("Faraday" or the "Company") (TSX:FDY) announces its financial results for the year ended December 31, 2025. Closed a ...
VANCOUVER, BC / ACCESS Newswire / March 12, 2026 / Faraday Copper Corp. ("Faraday" or the "Company") (TSX:FDY) announces its financial results for the year ended December 31, 2025. Highlights: 2025 ...
TVO Nuclear Services has signed a framework agreement to advise Estonia's Fermi Energia on its BWRX-300 SMR project targeting 2035 operation.
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that ...
Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results